RBC Capital analyst Shagun Singh raised the firm’s price target on Edwards Lifesciences to $101 from $95 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 earnings for Medical Devices. The sector fundamentals are “flashing positive signals” and the firm is expecting strong results, the analyst tells investors in a research note. RBC adds that sentiment on the stock is mostly positive heading into the Q1 earnings season as TAVR trends appear to be steady and as investors focus on the multi-billion TMTT – or Transcatheter Mitral and Tricuspid Therapies – opportunity that is yet to be meaningfully factored into estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $105 from $95 at Mizuho
- SMART data a ‘modest win’ for Medtronic, says Jefferies
- Edwards Lifesciences price target raised to $98 from $90 at Citi
- Edwards Lifesciences Announces Upcoming Board Chair Transition
- Edwards Lifesciences upgraded to Positive from Mixed view at OTR Global